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IKK2 is one of the most crucial signaling kinases for activation of the 
transcription factor NF-kappa B. Since many NF-kappa B activating 
pathways converge at the level of IKK2, we searched for interaction 
partners of this kinase using the C-terminal part (aa 466-756) as bait in 
a yeast two-hybrid system. We identified the N-terminal part (aa 1-
228) of the TNF-receptor associated factor TRAF1 as putative 
interaction partner, which was subsequently confirmed in mammalian 
cells by coimmunoprecipitation experiments. However, this interaction 
seemed weaker than the interaction between TRAF1 and TRAF2, an 
important activating adapter molecule of NF-kappa B signaling 
indicating that relative levels of IKK2, TRAF1 and TRAF2 might be 
important for the final biological readout. Reporter gene and kinase 
assays using ectopic expression of TRAF1 indicated that it can have 
both activating and inhibiting functions for IKK2 and NF-kappa B. Co-
expression of fluorescently tagged TRAF1 and TRAF2 at different ratios 
implied that TRAF1 can affect clustering and presumably the activating 
function of TRAF2 in a dose dependent manner. 
 
INTRODUCTION 
The NF-kappa B family of transcription factors is essential for a great 
variety of biological processes such as inflammation, cell survival, 
regulation of apoptosis, proliferation and cell differentiation. There are 
two major signaling pathways leading to NF-kappa B: the classical or 
canonical pathway originating at TNF-,  IL-1 or Toll-like receptors and 
the alternative pathway initiated for instance at CD40 [1]. Both 
pathways converge at the level of the IB kinase (IKK) complex, which 
consists basically of two related kinases (IKK1 and IKK2) and an essential 
adapter (termed NEMO for NF-kappa B essential modulator). The IB 
kinases can then phosphorylate inhibitors of NF-kappa B on two 
adjacent serine residues, marking them for polyubiquitination, which 
results in their degradation by 26S proteasomes and release of active 
NF-kappa B. The classical activation pathway signals primarily to IKK2, 
whereas the alternative pathway triggers predominantly IKK1 activity [1, 
2]. Nevertheless, these two kinases influence each other [3, 4] and 
interact with a variety of additional signaling molecules [1]. It is currently 
still not clear, which interactions can occur simultaneously and whether 
certain molecular associations are mutually exclusive or influence each 
other and as a consequence also the NF-kappa B signaling cascade. In 
the last few years, it became increasingly clear that ubiquitination 
processes exert important functions in the activation of the IKK complex 
[2]. These ubiquitinations are triggered by TRAF molecules (mainly 
TRAF2, TRAF5 and TRAF6), which contain RING domains that have E3 
ligase activity catalyzing non-degradative K63-linked polyubiquitination. 
In contrast to K48-linked polyubiquitin, K63-linked polyubiquitin chains 
do not lead to proteasomal degradation but rather serve as an 
association and signaling platform for certain ubiquitin binding proteins, 
such as TAB1 and TAB2 in combination with the kinase TAK1 [5]. K63-
linked polyubiquitination thereby results in binding and activation of 
TAK1, which then activates IKK2. TRAF1 is the only TRAF-adapter 
molecule lacking a RING domain and therefore does not act as a 
ubiquitinase [6, 7]. Of note, TRAF molecules form homo- or 
heterotrimeric complexes. It has been suggested that the composition of 
heterotrimers is important for signaling function. Interestingly, both 
positive and negative regulatory effects of TRAF1 on NF-kappa B 
signaling have been reported. In cell culture systems overexpression of 
TRAF1 resulted either in inhibition [8]  or in augmentation [9] of NF-
kappa B activity. Similar conflicting data have been obtained in knockout 
mouse models.  T-cells from TRAF1-deficient mice showed enhanced NF-
kappa B activity and increased IKK2 activity [10], whereas dendritic cells 
from TRAF1-deficient mice showed attenuated NF-kappa B signaling in a 
different study [11]. The effect of TRAF1 on signaling is further 
complicated by the fact that it is a substrate of caspases and therefore 
cleaved in the course of apoptosis. This leads to a release of the TRAF-
domain, which then acts as an inhibitor of NF-kappa B signaling [12].  
In this study we provide evidence for a specific interaction of TRAF1 with 
IKK2 and we demonstrate that this molecular association is weaker than 
TRAF1 / TRAF2 interaction. Based on this observation and the findings 
that ectopic expression of TRAF1 can have both inhibitory and 
stimulatory effects on IKK2 and NF-kappa B activity, we propose a 
model, in which relative levels of TRAF1, TRAF2 and IKK2 are important 
for regulating the signaling activity of IKK2.  
 
METHODS 
Yeast two-hybrid screening was performed with the C-terminal part of 
IKK2 (amino acids 466 – 756) essentially as described [13] using a library 
from activated leukocytes. After identification of TRAF1 as potential 
binding partner, all the TRAF molecules (TRAF1-TRAF6; kindly provided 
by David Sassoon, [14]) were tested in the yeast two-hybrid system for 
interaction with the IKK2 bait. Mammalian two-hybrid assays were 
performed with the Matchmaker™ system provided by Clontech 
according to the instructions of the manufacturer with the exception 
that the pFR-Luc vector from Stratagene was used in combination with a 
luciferase reporter gene assay as described in [15].  
Coimmunoprecipitations were carried out as specified in [16] using 
transfected HeLa cells and kinase assays were done as depicted in [13]. 
 
RESULTS AND DISCUSSION 
Our aim was to identify interaction partners of IKK2 as a key enzyme for 
NF-kappa B activation. To that end, we performed a yeast two-hybrid 
screening with the C-terminal part of IKK2 as bait. This part contains a 
helix-loop-helix domain and a leucine zipper as potential protein 
interaction domains. Among various signaling molecules, we also 
identified an N-terminal fragment of TRAF1 (amino acids 1 – 228) as 
putative binding partner. Next, we tested, whether other members of 
the TRAF family are capable of interacting with IKK2 using yeast two-
hybrid constructs for all TRAFs. In this system, only TRAF1 interacted 
with the IKK2-bait (Fig.1A). Testing IKK1 as bait in combination with all 
the TRAF molecules (TRAF1 – TRAF6) did not reveal any significant 
interaction (data not shown). The binding of IKK2 and TRAF1 could be 
verified in a mammalian two-hybrid reporter assay, demonstrating that 
the interaction was not an artifact of the yeast system (Fig. 1B). 
Furthermore, we could clearly demonstrate the interaction between full 
length IKK2 and full-length TRAF1 in human cells by applying co-
immunoprecipitation experiments (Fig. 1C). Similar experiments with the 
N-terminal part (aa 1 – 228) of TRAF1 verified the results of the yeast 
two hybrid system that the N-terminal domain lacking the TRAF domain 
is sufficient for the interaction with IKK2 (data not shown). However, it 
has to be noted that also the TRAF-domain seems to be capable of 
interacting with the IKK-complex [12]. In contrast to the co-precipitation 
of TRAF1 with IKK2, we could not detect any co-immunoprecipitation of 
TRAF2 with IKK2. Moreover, co-expression of TRAF2 reduced the 
amount of TRAF1 that was coprecipitated with IKK2 indicating that 
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TRAF2 might compete with IKK2 for TRAF1 binding (Fig. 1C). This 
possibility was further tested by co-immunoprecipitation of TRAF1 and 
TRAF2, which revealed that these two molecules interact with each 
other at a rather high NaCl concentration of 500 mM (Fig. 1D). At this 
salt concentration, we could not detect any significant interaction 
between TRAF1 and IKK2 (data not shown) indicating that TRAF1/TRAF2 
binding may be stronger than the association between TRAF1 and IKK2. 
As a consequence, it has to be expected that TRAF1 would rather bind 
TRAF2 as long as the later is not saturated. Specific interaction between 
IKK2 and TRAF1 but not other TRAF family members is supported by the 
fact that IKK2 interacts with the N-terminal part of TRAF1, which differs 
from all the other TRAF family members (Fig. 1e). The C-terminal 
interaction domain of IKK2 does not include the kinase domain, 
suggesting that it may still be accessible for substrates.   
 
Testing the effect of TRAF1 expression in NF-kappa B reporter gene 
assays revealed at first sight conflicting results. While TRAF1 clearly 
inhibited IKK2-mediated NF-kappa B activation in some experiments (Fig. 
2A), some expression constructs also led to stimulation of NF-kappa B 
activity in other experiments (Fig. 2A right). This variable effect was also 
observed in kinase assays, where TRAF1 resulted either in a slight 
inhibition of IKK2 activity (Fig. 2B, upper part), or in a significant 
stimulation of the activity (Fig. 2B, lower part). Interestingly, we could 
observe that another IKK2-interacting protein (Rpn5) also led to a 
stimulation of IKK2 activity in the later case. A possible explanation for 
this phenomenon is that IKK2 interacting proteins might trigger 
clustering of IKK2 molecules and subsequent self-activation by auto-
phosphorylation. According to this hypothesis the level of the IKK2 
interacting molecules relative to the amount of IKK2 might be important 
for exerting either a stimulatory or an inhibitory effect. This model can 
also be applied to other interaction partners of TRAF1. Since TRAF2 is an 
important positively acting signaling molecule interacting with TRAF1, 
we also tested the effect of TRAF1 on TRAF2. Upon ectopic expression as 
a fluorescent fusion protein in cells, TRAF2 forms distinct clusters in the 
cytosol. This is most likely reflecting the inherent propensity of TRAF2 to 
trigger the oligomerization of other signaling molecules or kinases by 
self-interaction via the TRAF-domain. Co-expression of a CFP-tagged 
TRAF1 with YFP-tagged TRAF2 resulted in a dose dependent 
disaggregation of the TRAF2 clusters, revealing that TRAF1 has the 
capability of influencing the oligomerization of TRAF2 (Fig. 3) important 
for its signaling function. 
 
Of note, TRAF1 is transcriptionally upregulated by NF-kappa B [7, 9], and 
degradation of TRAF2 is triggered by the NF-kappa B signaling pathway 
[6, 7]. The combination of these two effects is expected to shift the 
 
Fig. 2: TRAF1 can exert both inhibitory and stimulatory effects on 
IKK2 and NF-kappa B activity. A) Effect of TRAF1 in NF-kappa B 
reporter gene assays. Left panel: 293 cells were transfected with a NF-
kappa B luciferase reporter and IKK2 in absence or presence of a 
TRAF1 expression construct. Right panel: HeLa cells were transfected 
with the NF-kappa B reporter and two different TRAF1 constructs as 
indicated followed by treatment with TNF (50 ng/ml for 6 h). B) 
Effect of TRAF1 on IKK2 activity. Upper left panel: In vitro kinase 
assay using IKK2 immunoprecipitated from 293 cells transfected with 
IKK2 alone or in combination with TRAF1. Upper right: quantification 
of phosphorylated IB and auto-phosphorylated IKK2. Lower left 
panel: Kinase assay and Western Blot of IKK2 or mutant IKK2 (IKK2-
mut) in combination with TRAF1 or the IKK2 interacting protein Rpn5. 
Lower right: Quantification of IB phosphorylation. 
 
 
 
Fig. 1: IKK2 interacts specifically with TRAF1. A) Yeast two hybrid 
assay: The C-terminal domain of IKK2 interacts specifically with 
TRAF1 but not TRAF2 – TRAF6.  B) Verification of the interaction in 
mammalian cells using a mammalian two-hybrid system. A Luciferase 
reporter assay was done with empty (-) bait or prey constructs, IKK2, 
TRAF1 or control as indicated. C) Coimmuno-precipitation of IKK2 
and TRAF1 after transfection of HeLa cells with flag- or HA-tagged 
expression constructs as indicated and immunoprecipitation (IP) in 
presence of 250 mM NaCl. D) Coimmuno-precipitation of TRAF1 and 
TRAF2 in presence of 500 mM NaCl. E) Schematic illustration of the 
interaction domains as depicted by the overlapping rectangle. Amino 
acids 466-756 of IKK2 including a leucine zipper (LZ), a helix-loop-
helix domain (HLH) and the NEMO binding domain (NBD) interact 
with amino acids 1 – 228 of TRAF1 (containing a Zn-finger). 
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balance of the TRAF1/TRAF2 ratio and might therefore lead to a shift 
from TRAF1/TRAF2 complexes to TRAF1/IKK2 complexes. This has 
potential consequences for IKK2 and NF-kappa B activity dependent on 
the cellular context and the relative levels of TRAF1 and IKK2. Since 
TRAF1 does not contain a RING domain for K63-linked 
polyubiquitination, it might be expected that it is not an activator of the 
NF-kappa B pathway by itself, but rather an inhibitor. However, since 
TRAF1 binds other TRAF molecules which are activators of NF-kappa B 
signaling, it may also function as an activator in conjunction with these 
proteins at a certain stoichiometry. Moreover, binding of TRAF1 to IKK2 
may also directly influence IKK2 activity by affecting proximity-induced 
auto-phosphorylation and self-activation of IKK2. Taken together it 
seems likely that TRAF1 exerts variable regulatory functions in NF-kappa 
B signaling dependent on the presence and relative levels of other 
signaling molecules and the cellular context. 
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Fig. 3: TRAF1 influences the clustering tendency of TRAF2 
in a dose dependent manner. YFP-tagged TRAF2 was 
expressed either alone or in combination with CFP-tagged 
TRAF1 in 293 cells at a ratio of 1:1 or 1:9 as indicated. A 
higher level of TRAF1 led to the disaggregation of TRAF2 
clusters. 
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